The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells

The supramolecular processing of liposomal doxorubicin hinders its therapeutic efficacy in cells

The successful trajectory of liposome-encapsulated doxorubicin (e.g., Doxil, which has been approved by the U.S. Food and Drug Administration) as an anticancer nanodrug in clinical applications is contradicted by in vitro cell viability data that highlight its reduced efficacy in promoting cell deat...

Full description

Saved in:
Bibliographic Details
Main Authors: Annalisa Carretta, Aldo Moscardini, Giovanni Signore, Doriana Debellis, Federico Catalano, Roberto Marotta, Valentina Palmieri, Giulia Tedeschi, Lorenzo Scipioni, Daniela Pozzi, Giulio Caracciolo, Fabio Beltram, Francesco Cardarelli
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Molecular Therapy: Oncology
Subjects:
doxorubicin
liposomal doxorubicin
Doxil
Doxoves
fluorescence
FLIM
Online Access:http://www.sciencedirect.com/science/article/pii/S295032992400078X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S295032992400078X

Similar Items